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Abstract 
The present study assesses the clinical usefulness of the hepatitis C core antigen assay for monitoring of 
patients being treated for chronic hepatitis C virus (HCV) infection. Eighty-six serum samples were selected 
at random from 16 patients and levels of HCV RNA and HCV core antigen were determined simultaneously 
and in parallel to compare both techniques. The data obtained were compared by Pearson’s correlation and 
the coefficients calculated by Fisher transformation and by calculating the difference and standard error. A 
good linear correlation was observed between both techniques. Maximum correlation, with significant 
difference, was found between patients infected with the 1a genotype and other genotypes. In conclusion, the 
HCV core antigen assay is useful for the diagnosis of early infection; however, its use for determining the 
exact timing of viral elimination during treatment is clearly unsuitable. 
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1. Introduction 
The presence of hepatitis C virus (HCV) can be demonstrated by direct detection techniques 
using monoclonal antibodies that recognize specific viral antigens. Chemiluminescent substrates 
and photometry are used frequently, given the high sensitivities achieved. Although HCV infection 
does not induce high viremia, attempts to develop procedures for antigen detection in serum date 
back to 1992 (Katayama et al., 1992; Tanaka et al., 1995; Kashiwakuma et al., 1996; Orito et al., 
1996; Tanaka et al., 1996; Jolivet-Reynaud et al., 1998; Masalova et al., 1998; Kobayashi et al., 
1998). The target of these assays was the core protein of HCV, since it is the most abundant 
protein in the virion and its immunodominant epitopes are well-conserved in different strains. 
Although the performance of these methods seemed promising, it was not until 1999 that the first 
useful report was published. In the original description (Aoyagi et al., 1999), this method was able 
to detect antigen concentrations of up to 0.06 pg/ml, roughly 500 copies per ml. Moreover, it was 
able to detect infections in any serotype. The correlations with the PCR techniques ranged from 
94% to 96%. The presence in the sample of substances, such as anticoagulants, hemoglobin, 
rheumatoid factor, bilirubin or lipids, that could possibly interfere with these assays had no effect 
on the method. The linear response range was broad and the coefficient of variation between 4% 
and 7.9%. After the optimization and standardization of the use of detergents (Peterson et al., 
2000), a new method for the detection of core antigen in serum was developed. This method was 
able to detect viremia in all stages of infection and not only in the antibody negative window 
phase. In the first studies, the cutoff value was 2.3 pg/ml, which was equivalent to 50,000 IU/ml, 
measured by PCR (Icardi et al., 2001). However, more recent studies have demonstrated that it is 
possible to reduce the cutoff value of the assay to 1.5 pg/ml without loss of specificity (Zanetti et 
al., 2002; Picchio, 2002). The present study aims to assess the clinical usefulness of this new 
technique for monitoring patients under treatment for chronic HCV infection. 
2. Materials and methods 
This study was conducted at the Department of Internal Medicine B of Juan Canalejo Hospital 
(La Coruña, Spain) during 2002. Prior informed consent was obtained from all patients. Serum 
samples were obtained from the serum bank of the hospital and stored at −85 °C until use. Eighty-
six serum samples were selected at random from 16 patients with chronic HCV hepatitis on 
different antiviral treatment schedules (interferon alpha plus ribavirin) and then tested 
simultaneously and in parallel to determine: 
 
1. HCV RNA using the Cobas Amplicor Monitor kit (Roche version 2.0), following the 
manufacturer’s instructions. The results, expressed in IU/ml, ranged from 250 to 800,000. This 
method is a PCR-based quantitative and non-competitive assay. The process included RNA 
extraction and reverse transcription and amplification from the 5′-untranslated region using 
primers. The samples and the quantitation standard were detected by hybridization using a 
biotinylated-labelled probe. All procedures, except for the extraction step, were automated. 
2. HCV core antigen tests using a Trak-C ELISA kit (Chiron-Ortho, Ortho-Clinical Diagnostics, 
Johnson & Johnson Company), following the procedure recommended by the manufacturer. 
This is a microplate test, consisting of a two-step manual immunoassay that uses several 
monoclonal antibodies with specificity for different regions of the HCV core antigen. The 
antibodies covering the surface of the microplate bind the antigen and Fab fragments of the 
horseradish peroxidase-conjugated monoclonal antibodies unite with the bound antigen. HCV 
core antigen levels ranged between a maximum value of 160 pg/ml and a minimum of 0 pg/ml. 
  
Briefly, the protocol involved four stages: 
 
(a) Prior to starting the assay, samples were incubated with pretreatment reagent in uncoated 
microplates, as indicated in the protocol (Ortho-Clinical Diagnostics Chiron-Ortho Trak-C 
Protocol of Use), to break any immunocomplexes formed. 
(b) The pretreated sample was diluted and incubated in a microplate coated with monoclonal 
antibodies that bind the immunoreactive HCV core antigen. At the end of the incubation, the 
microplate was washed to remove unbound material. 
(c) The conjugate (Fab fragments of monoclonal antibodies conjugated to peroxidase) was added 
to the microplate and the mixture incubated. The conjugate binds the antigen attached to the 
antibodies on the surface of the microplate. The plate was washed again to eliminate unbound 
material. 
(d) An enzymatic detection system composed of o-phenylendiamine (OPD) and hydrogen 
peroxide was added to the microplate. In the presence of bound conjugate, OPD is oxidized, 
yielding a reddish product. In this reaction, peroxidase is oxidized divalently by hydrogen 
peroxide to form an intermediate compound that is also reduced to the initial state by a 
subsequent interaction with the hydrogen ion donated by OPD. The resulting form of OPD is 
orange and the color intensity is proportional to the amount of core antigen present in the plate. 
This is measured in a photometer at 490 or 492 nm with a reference filter at 620 or 630 nm. 
 
Genotyping was carried out prior and during testing of one sample from each patient by INNO-
LiPA (Boehringer-Ingelheim), according to the standard method described by the manufacturer. 
Data comparisons were performed by Pearson’s correlation coefficient (confidence interval P < 
0.05, unless otherwise indicated). Comparison of the coefficients calculated was carried out by 
Fisher transformation and by calculating the difference and standard error. 
3. Results 
Eighty-six samples from 16 patients (mean of samples per patient was 5.3 with a maximum of 
12 and a minimum of 4) were studied. The distribution of sample genotypes was 51% for 1b and 
the rest were grouped as shown in Fig. 1. Using the sample analysis by PCR as a reference, the 
distribution of viral RNA expressed in IU/ml showed that over 50% of the samples appeared at 
end values (>700,000 and <100,000 IU/ml), as depicted in Table 1. 
 
 
 
Fig. 1. Genotype distribution in the sample group. 
  
Table 1. Sample distribution as a function of viral load 
Viremia RNA (IU/ml) % Number of cases 
   
>800,000–700,000 27.9 24 
700,000–500,000 10.4 9 
500,000–300,000 12.7 11 
300,000–100,000 13.9 12 
100,000–<250 34.8 30 
   
 
To compare both techniques, a correlation study was undertaken between the continuous 
quantitative values of viral load, expressed in pg/ml of core antigen in serum, and viral RNA in 
IU/ml. Good linear correlation was observed, giving a Pearson’s correlation coefficient value of 
0.887 that was significant with P < 0.001. 
 
Hence, there is strong positive correlation between the two techniques, as seen in Fig. 2. To 
extrapolate these results to the population, the confidence interval of the correlation coefficient 
was calculated for a confidence interval of 99% (P < 0.01), obtaining maximum and minimum 
values of 0.943 and 0.781, respectively. Both were within the significance level for a sample of 86 
cases. This strong correlation was maintained throughout the entire range, except at the lower and 
upper limits. In Table 2, the correlation coefficient is expressed for RNA values from 800,000 to 
250 IU/ml, grouped according to levels of viremia. It also depicts the confidence intervals for P < 
0.05. However, differences between the plots were not significant. 
 
 
 
Fig. 2. Linear correlation calculated of viral RNA vs. core Ag. 
  
Table 2. Correlation coefficient as a function of viral load 
Viremia RNA (IU/ml) Correlation coefficienta 
  
>800,000–700,000 0.157 (−0.4 to 0.5) 
700,000–500,000 −0.12 (−0.6 to 0.59) 
500,000–300,000 0.41 (−0.6 to 0.81) 
300,000–100,000 0.66 (−0.58 to 0.90) 
100,000–<250 0.32 (−0.36 to 0.61) 
  
 
a Correlation coefficient with confidence interval (P < 0.05). 
Once the existence of correlation was established, formulaes of linear regression were 
calculated using the data points, where the amounts of antigen and RNA were obtained, 
respectively, as 
 
antigen(pg/ml) = 0.000158RNA (UI/ml) 
 
RNA(UI/ml) = 5590Ag(pg/ml), 
 
 
assuming 0 pg/ml = 0 IU/ml. The correlation was equally good for each of the genotypes present 
in the sample group, varying between 0.75 and 0.99. Differences between correlation coefficients 
were analyzed and maximum correlation, with significant difference (P < 0.05), was found for 
patients having 1a genotype when compared with the other genotypes. Significant differences 
were not found for the other genotypes (Table 3). 
Table 3. Correlation coefficient as a function of viral genotype 
Genotype Correlation coefficienta 
  
3a 0.934 (0.72–0.97) 
1a 0.991 (0.98–1) 
1b 0.88 (0.79–0.94) 
2a/2c 0.753 (0.5–0.95) 
  
 
a Confidence interval (P < 0.05). 
Finally, a qualitative comparison (whether positive or negative for viremia) of both techniques 
was performed to assess the sensitivity and specificity of this new technique (Table 4). The cutoff 
values of RNA in serum were set at 250 IU/ml for the PCR technique and 1 pg/ml for the HCV 
core antigen technique. In the sample group studied, specificity (the probability of a negative 
patient being evaluated accurately) was 0.4, that is, two out of a total of five patients were 
negative; however, sensitivity (the probability of the result being positive when the patient was 
positive) was 0.959. The predicative value for a negative result was 0.166, that is, the probability 
of a negative value being real is low in this series (in fact, the number of false negatives surpassed 
the real negative values). In contrast, the predicative value for a positive result was high, showing 
a value above 0.9. Three antigen positive, PCR negative samples were found and all showed low 
levels of Ag (1.2–3 pg/ml). For other factors studied (age, sex, evolution of the infection or degree 
of inflammatory activity), no significant differences were found in the correlation of both methods. 
Table 4. Qualitative comparison of both techniques 
 
RNA+ RNA− Total 
    
Positive antigen 71 3 74 
Negative antigen 10 2 12 
Total 81 5 86 
    
 
4. Discussion 
The results show excellent correlation between the HCV core antigen detection technique and 
the PCR-based method, especially at intermediate values, between 100,000 and 500,000 IU/ml of 
viral RNA. In comparison with PCR analyses, the clinical sensitivity of the HCV core antigen 
detection technique was close to 100% in at least three independent studies (Tanaka et al., 2000; 
Bouvier-Alias et al., 2002; Shah et al., 2003). In the chronic stage of infection, correlation with the 
PCR technique ranged between 88.5% and 100% (Peterson et al., 2000; Picchio, 2002; Lee et al., 
2001; Bahl et al., 2001). With reference to monitoring treatment, thus far, a good correlation was 
shown between the method presented and quantitative PCR, fluctuating between 87% and 100% 
(Tokita et al., 2000; Busch et al., 2001). These sensitivities are accompanied by a specificity 
between 99.2% and 99.9% after studying more than 1350 negative samples (Busch et al., 2001; 
Bahl et al., 2001). However, this excellent relation at intermediate values deteriorates as limit 
values of distribution were reached. This phenomenon could be related at least in part to the fact 
that both techniques have a limit; hence, values outside of this range are no longer linear and 
extrapolation is not possible. The same occurred with values near the upper limit, linearity also 
being lost progressively. In this study, only 37% of samples were within the linear range of the 
assay.The minimum values obtained in the sample group also showed diminished correlation. As 
described in the literature, in general, this lack of correlation is produced in samples with viremia 
in the order of 1000 copies per ml. The clinical relevance of these errors is debatable, given in the 
early phases of infection, the correlations are high (the viral loads are within the range) and for the 
same reason, this technique also serves to detect early responders (Zanetti et al., 2002), for early 
prediction of the response (Bahl et al., 2001) and the absence of this response (Zanetti et al., 2002) 
in treated patients. The presence of low viremia in intermediate phases of treatment (where the 
discrepancies are found) could affect the ability of the method to identify patients who have a 
relapse after treatment. Nonetheless, the method offers linear quantitation between 2.3 and 
100 pg/ml with a specificity of 99.2% and variation coefficient between 7% and 33% (Busch et al., 
2001). 
 
The core antigen technique examined in the present study showed low negative predicative 
value (due to the low number of RNA negative patients in the sample, 5 out of 86); however, this 
predicative value would be higher in the general population, where there are more non-infected 
patients and viremia below 5 logs is infrequent. This limitation in detecting the absence of viremia 
should be considered when using this technique to monitor patients during treatment. These 
findings have been reported in previous studies (Zanetti et al., 2002; Bahl et al., 2001; Busch et al., 
2001) and undoubtedly are due to the presence of low viremia in this group of patients. 
  
It is true that some studies noted the lack of correlation as a function of the different viral 
characteristics, for example, the presence of certain mutations (Tokita et al., 2000), yet the 
correlation difference in favor of a particular genotype is striking, specifically because it is clear 
when compared with each of the other genotypes. There is no explanation for the phenomenon, 
since when other factors that could possibly be involved, such as magnitude of viral load, are 
studied, no significant differences are found. To the best of our knowledge, this finding has not 
been described in the literature. 
 
There is good correlation between the measurements of viral RNA and of core antigen in the 
serum of patients with chronic infection by HCV under treatment. This correlation was maintained 
throughout the entire range of RNA values and it was apparently better for intermediate viral loads 
(100,000–300,000 IU/ml), although it never reached significant differences. If only the ability of 
the test to distinguish between positive and negative patients for circulating virus is considered, 
this method is useful for the diagnosis of early infection. Although it is easier and cheaper than 
PCR–RNA, it is clearly inappropriate for determining the exact moment of viral elimination 
during treatment. In studying other factors that could influence the degree of correlation, it was 
found incidentally that this correlation was significantly greater between patients infected with the 
1a genotype, independently of the level of viral load or the number of cases studied, which 
requires further study. 
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